Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;6(2):132-142.
doi: 10.1007/s40501-019-00171-1. Epub 2019 Apr 29.

Augmenting Treatment for Posttraumatic Stress Disorder and Co-Occurring Conditions with Oxytocin

Julianne C Flanagan  1 , Jennifer M Mitchell  2   3
Affiliations

Augmenting Treatment for Posttraumatic Stress Disorder and Co-Occurring Conditions with Oxytocin

Julianne C Flanagan et al. Curr Treat Options Psychiatry. 2019 Jun.

Abstract

Purpose of review: The goal of this manuscript is to review the extant literature examining the neurobiological and behavioral mechanisms underlying the potential utility of intranasal oxytocin as a novel pharmacologic intervention for the treatment of posttraumatic stress disorder (PTSD), and for the treatment of co-morbid PTSD and alcohol and substance use disorders.

Recent findings: Research indicates that intranasal oxytocin is a low-cost and easily accessible medication with an excellent safety profile. Oxytocin holds promise for facilitating more effective PTSD treatment, particularly when used in combination with evidence-supported psychotherapy interventions. There is still a significant need to identify the mechanisms of action underlying oxytocin treatment of PTSD, and to maximize methods of nasal spray delivery, examine dose-response outcomes, and clarify the characteristics of individuals and populations that are most likely to benefit from adjunctive oxytocin treatment.

Summary: Collectively, preclinical and human laboratory research suggest that oxytocin may be an effective mechanism by which treatment outcomes for PTSD and common comorbidities can be enhanced. Adequately powered randomized controlled trials are needed to address efficacy, identify predictors of treatment outcome, and to assess the use of intranasal oxytocin within appropriate PTSD populations.

Keywords: comorbidity; medication-enhanced psychotherapy; oxytocin; posttraumatic stress; treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest. The authors have no conflict of interest to declare.

References

    1. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 2012;21:169–84. - PMC - PubMed
    1. Tanielian T, Haycox LH, Schell TL, Marshall GN, Burnam MA, Eibner C, et al. Invisible Wounds of War Summary and Recommendations for Addressing Psychological and Cognitive Injuries. DTIC Document; 2008.
    1. Pietrzak RH, Goldstein RB, Southwick SM, Grant BF. Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: Results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Anxiety Disord 2011;25(3):456–65. - PMC - PubMed
    1. Petrakis IL, Rosenheck R, Desai R. Substance Use Comorbidity among Veterans with Posttraumatic Stress Disorder and Other Psychiatric Illness. The American Journal on Addictions. 2011;20(3):185–9. - PubMed
    1. Kilmer B, Eibner C, Ringel JS, Pacula RL. Invisible wounds, visible savings? Using microsimulation to estimate the costs and savings associated with providing evidence-based treatment for PTSD and depression to veterans of Operation Enduring Freedom and Operation Iraqi Freedom. Psychological Trauma: Theory, Research, Practice, and Policy; 2011;3(2):201–11.

LinkOut - more resources